Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Expected to Achieve 6.8% CAGR by 2029: Growth Forecast Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Size By 2025?
The market size for benign prostatic hyperplasia (BPH) treatment devices and equipment has seen considerable growth in recent times. It's projected to increase from $1.29 billion in the year 2024 to a staggering $1.38 billion in the year 2025, with a compound annual growth rate (CAGR) of 7.2%. The growth witnessed in the historic period is due to factors such as the aging population, heightened awareness and diagnosis, access to healthcare and individualized treatments.

How Big Is the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Size Expected to Grow by 2029?
Expectations are high for the benign prostatic hyperplasia (BPH) treatment devices and equipment market, as robust growth is projected over the next several years. The market size is forecasted to reach $1.8 billion by 2029, expanding at a compound annual growth rate (CAGR) of 6.8%. Factors contributing to this growth in the estimated period include advancements in minimally invasive techniques, expansion in emerging markets, supportive regulatory frameworks, and value-driven healthcare. Trending in this forecast timeframe are non-invasive and office-based procedures, the utilization of laser and radiofrequency technologies, the rise of telemedicine and remote consultations, and an increased emphasis on patient education and engagement.

View the full report here:
https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-bph-treatment-devices-and-equipment-global-market-report

Which Key Market Drivers Powering Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Expansion and Growth?
The projected surge in instances of prostate cancer is expected to bolster growth in the benign prostatic hyperplasia market. Prostate cancer is a variety that forms in the prostate gland, which is a petite gland akin to a walnut in size, situated right beneath the bladder in men. A rise in instances of prostate cancer generally contributes to an increased count of elderly males seeking help for prostate-related problems. Consequently, this leads to the discovery and management of benign prostatic hyperplasia. For example, the American Society of Clinical Oncology (ASCO), a professional organization based in the US that circulates patient data via the cancer.net website, stated in February 2023 that an estimated 288,300 men in the United States were diagnosed with prostate cancer in 2023, and 268,490 new cases surfaced with 34,500 deaths occurring from prostate cancer in 2022. Hence, the surge in prostate cancer instances is fueling the growth of the benign prostatic hyperplasia market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2431&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market?
Prominent organisations in the benign prostatic hyperplasia market are striving to innovate products like the UroLift 2 System and the UroLift ATC advanced tissue control system to deliver dependable solutions in the market. These systems are introduced for treating lower urinary tract symptoms brought about by benign prostatic hyperplasia (BPH). In May 2022, for example, the UroLift 2 System and UroLift ATC were launched by Teleflex Incorporated, a medical device firm based in the US. The UroLift 2 System is a delivery model crafted to reach the prostatic urethra and place lasting UroLift implants through the prostate lobes, while the UroLift ATC advanced tissue control system offers a minimally invasive method to manage the symptoms of an enlarged prostate. This innovative procedure addresses BPH by lifting and holding the swollen prostate tissue so it no longer obstructs the urethra.

What Are the Emerging Segments in the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market?
The benign prostatic hyperplasia (BPH) treatment devices and equipment market covered in this report is segmented -

1) By Product: Resectoscopes, Radiofrequency Ablation Device, Urology Lasers, Prostatic Stents, Implants
2) By Procedure Type: Transurethral Needle Ablation (TUNA), Transurethral Resection Of Prostate (TURP), Transurethral Incision Of Prostate (TUIP), Transurethral Microwave Thermotherapy (TUMT), Laser Surgery, Other Procedure Types
3) By End-User: Hospitals, Ambulatory Surgical Centres (ASC), Clinics, Home

Subsegments:
1) By Resectoscopes: Bipolar Resectoscopes, Monopolar Resectoscopes, High-Performance Resectoscopes
2) By Radiofrequency Ablation Device: Single-Needle Radiofrequency Ablation, Multi-Needle Radiofrequency Ablation
3) By Urology Lasers: Holmium Lasers, Diode Lasers, Green Light Lasers
4) By Prostatic Stents: Temporary Prostatic Stents, Permanent Prostatic Stents
5) By Implants: Prostatic Urethral Lift (PUL) Implants, Balloon-Expandable Stents, Permanent Implants for BPH Treatment

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=2431&type=smp

Who Are the Global Leaders in the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market?
Major companies operating in the benign prostatic hyperplasia (BPH) treatment devices and equipment market include Karl Storz, Lumenis Ltd., Olympus Corporation, Urologix LLC, Boston scientific Inc., Endo International plc, NeoTract Inc., OmniGuide Inc., Medifocus Inc., ProArc Medical Ltd., Teleflex Incorporated, Medtronic plc, Urotech Devices, Prostalund Operations AB, Baxter International, NxThera Inc., Richard Wolf GmbH, Coloplast A/S, Siemens Healthineers, Quest Pharmatech, Protox Therapeutics, IntelGenx Technologies Corp, Astellas Pharma Inc., Ipsen S.A., Biolitec AG, BVM Medical, Convergent Laser Technologies, Cook Medical, GreenLight Technologies, Merit Medical Systems, Pnn Medical A/S, PROCEPT BioRobotics, Prosenex, ProSolv CardioVascular Inc., Quanta System, Rocamed SAM, RZ Medizintechnik GmbH, SRS Medical Systems, UroShape LLC, Vertebron Inc.

Which are the Top Profitable Regional Markets for the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Industry?
North America was the largest region in the benign prostatic hyperplasia (BPH) treatment devices and equipment market in 2023. Western Europe was the second-largest region in the global benign prostatic hyperplasia (BPH) treatment devices and equipment market. The regions covered in the benign prostatic hyperplasia (BNH) treatment devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2431

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.